ATAI acquired for $3.8 billion by Lilly, Cathie Wood states

ATAI acquired for $3.8 billion by Lilly, Cathie Wood states
ATAI sold to Lilly for $3.8 billion

Cathie Wood, fund manager at ARK Invest, highlights that Christian Angermayer is selling his psychedelic biotech company ATAI for approximately $3.8 billion to Lilly, the largest biotech company in the world.

Wood notes that this transaction marks a well-deserved return for ATAI shareholders and validates the mission and vision of the company.

Wood has previously noted that capital outflows from unstable countries can increase demand for bitcoin and digital assets, according to a recent article on crypto markets. She has also argued that the U.S. Federal Reserve is likely to support economic growth if inflation falls to 0–1%, as outlined in a separate commentary. These views highlight her ongoing focus on market responses to major economic events.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.